Jean-Michel Dogné on The Aspirin Dosing after Trump’s Announcement
Jean-Michel Dogné, Full Professor and Dean of the Faculty of Medicine at Namur University, shared on LinkedIn:
”Approximations and blatant errors…
From the great Trump
- The aspirin (ASA) does not “thin” or “liquefy” the blood!
Acetylsalicylic acid has no effect on blood viscosity.
Its mechanism of action is well known:
- inhibition of platelet aggregation,
- by irreversibly blocking platelet COX-1,
- leading to a decrease in thromboxane A₂ synthesis.
Talking about “thick blood” or “thin blood” is therefore a misleading simplification with no pathophysiological basis.
2. In cardiovascular (secondary) prevention, we are not talking about high doses!
The recommendations are very clear:
- Low-dose ASA, generally 75 to 100 mg per day.
Furthermore, in patients aged ≥ 70 with no history of cardiovascular disease, data show no net benefit from low-dose ASA and a significant increase in major bleeding!
In practice, the recommendations therefore advise against initiating ASA for primary prevention in these patients.”
Stay updated with Hemostasis Today.
-
Jul 8, 2026, 14:17Maha Othman: Advancing Thrombosis and Hemostasis Research at ISTH 2026
-
Jul 8, 2026, 14:07Zain Khalpey: Atrial Fibrillation as the Hidden Driver of Preventable Ischemic Stroke
-
Jul 8, 2026, 11:33Ifeanyichukwu Ifechidere: Haemophilia A and B – From First Diagnosis to the Era of Gene Therapy
-
Jul 8, 2026, 10:29Bringing Hemophilia Care Closer to Communities in Togo – WFH
-
Jul 8, 2026, 10:12Natasha Jolakoski: Completing Advanced Training in Thrombosis and Hemostasis
-
Jul 8, 2026, 09:58Rola Ghasoub: Early Intracranial Hemorrhage Remains the Main Barrier to Cure in Acute Promyelocytic Leukemia
-
Jul 8, 2026, 05:53Excellent PhD Defense by Roberta Cirsmaru on Gene Therapy for Hemophilia A – CRH French Reference Center for Hemophilia Lyon
-
Jul 8, 2026, 05:48Riccardo Menandro: How Lipid Nanoparticles Are Shaping the Future of Rare Disease and Hemophilia Treatment
-
Jul 8, 2026, 05:39Daniel Victor Ortigoza: New Evidence from ATLANTIS-4D-CT on Apixaban and Subclinical Valve Thrombosis